Tango Therapeutics, Inc. (TNGX)
Market Cap | 344.81M |
Revenue (ttm) | 43.38M |
Net Income (ttm) | -123.40M |
Shares Out | 107.42M |
EPS (ttm) | -1.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 168,467 |
Open | 3.100 |
Previous Close | 3.100 |
Day's Range | 3.010 - 3.210 |
52-Week Range | 2.700 - 13.010 |
Beta | 0.75 |
Analysts | Strong Buy |
Price Target | 13.14 (+309.35%) |
Earnings Date | Nov 6, 2024 |
About TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencin... [Read more]
Financial Performance
In 2023, Tango Therapeutics's revenue was $36.53 million, an increase of 46.93% compared to the previous year's $24.86 million. Losses were -$101.74 million, -5.95% less than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $13.14, which is an increase of 309.35% from the latest price.
News
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, repo...
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, anno...
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX...
Tango Therapeutics to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, repo...
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
Tango Therapeutics to stop development of cancer therapy
Tango Therapeutics said on Thursday it would stop the development of its experimental cancer therapy due to liver toxicity experienced by patients in an early-to-mid stage trial.
Tango Therapeutics Announces Discontinuation of TNG348 Program
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, toda...
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, repo...
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, repo...
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs
Tango Therapeutics, a biotech company focused on synthetic lethality and PRMT5 inhibition, has two PRMT5 inhibitors in clinical development. Tango's shares spiked after positive data from Mirati Thera...
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
STOCKHOLM , Jan. 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers –
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 –
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Circling Bank On Tango Therapeutics
We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027,...
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision canc...
Tango Therapeutics Announces Updates to Its Board of Directors
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Stock Surges On Peer Data Merits Excitement And Perspective
Tango Therapeutics is advancing in cancer treatment with Phase 1/2 clinical trials for TNG908 and TNG462, targeting MTAP-deleted tumors. Tango's stock soared by over 100% following Mirati's announceme...
Tango Therapeutics Announces $80 million Private Placement Financing
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...